Merrimack's Mulroy on Success of Pancreatic Drug Onivyde(Audio)

(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Bob Mulroy, CEO of Merrimack Pharmaceuticals, on biotech earnings, consumer health and oncology, and its product pipeline. Broadcasting live from the Boston Convention and Exhibition Center.